Faricimab is currently under patent protection, meaning it has not yet reached loss of exclusivity [1][2]. Exclusivity is generally determined by patent expiry dates and any regulatory exclusivities granted [1][3].
When does Faricimab's patent expire?
The specific expiry dates for Faricimab's patents are not publicly detailed in the provided information. However, patent protection for novel drugs typically lasts for a significant period, often around 20 years from the filing date, though this can be extended through various mechanisms [1][3].
What does loss of exclusivity mean for Faricimab?
Loss of exclusivity for Faricimab would occur after its patent and any associated regulatory exclusivities expire [1]. This would open the door for the development and potential approval of biosimilar versions of the drug by other manufacturers [2][4].
What are biosimilars and how do they relate to Faricimab?
Biosimilars are biological products that are highly similar to an already approved biological medicine (the reference product), with no clinically meaningful differences in terms of safety, purity, and potency [4]. Once Faricimab loses exclusivity, companies could seek approval for biosimilar versions, which would likely offer more affordable treatment options [2][4].
Who develops Faricimab and its potential biosimilars?
Faricimab is developed by Roche and Genentech [5]. Following patent expiry, other pharmaceutical companies that specialize in biosimilar development may seek to market their own versions of Faricimab [2][4].
What is Faricimab used for?
Faricimab is a bispecific antibody designed to target angiopoietin-2 (Ang-2) and vascular endothelial growth factor A (VEGF-A) [5]. It is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME) [5].
What are the clinical implications of Faricimab?
Clinical trials have shown that Faricimab can effectively treat wet AMD and DME, offering sustained vision gains and reducing treatment burden by allowing for less frequent dosing compared to some existing therapies [5]. The development of biosimilars post-exclusivity could expand patient access to these types of treatments [2][4].
---
Sources:
[1] https://www.fda.gov/drugs/patent-term-restoration/patent-exclusivity
[2] https://www.fda.gov/drugs/abbreviated-new-drug-applications-anda/biosimilars-and-interchangeable-biosimilars
[3] https://www.uspto.gov/patents/basics/term-and-maintenance-fees
[4] https://www.ema.europa.eu/en/human-regulatory/overview/advanced-therapy-medicinal-products/biosimilar-medicinal-products
[5] https://www.roche.com/media/releases/med-2022-01-10